Literature DB >> 6979959

Effects of bacterial pneumonitis on development of pneumocystosis in rats.

E L Pesanti.   

Abstract

Disease caused by the protozoan parasite Pneumocystis carinii complicates management of patients with a variety of defects in immune function and is most commonly observed in patients who receive long-term therapy with glucocorticoids. In the rat, disease is readily induced by chronic administration of glucocorticoids. However, rats that have had polymorphonuclear leukocytic pneumonitis induced by Pseudomonas are protected from development of pneumocystosis, whereas rats that have received an intratracheal injection of Staphylococcus, which does not induce a polymorphonuclear leukocytic alveolar exudate, are not protected. It is possibly that accidental contact of polymorphonuclear leukocytes with dormant Pneumocystis is an important element of control of the organism in healthy animals, and suppression of polymorphonuclear leukocytic inflammatory response underlies glucocorticoid-induced and spontaneous activation of the disease.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6979959     DOI: 10.1164/arrd.1982.125.6.723

Source DB:  PubMed          Journal:  Am Rev Respir Dis        ISSN: 0003-0805


  10 in total

1.  A new model of Pneumocystis carinii infection in mice selectively depleted of helper T lymphocytes.

Authors:  J Shellito; V V Suzara; W Blumenfeld; J M Beck; H J Steger; T H Ermak
Journal:  J Clin Invest       Date:  1990-05       Impact factor: 14.808

2.  Pneumocystis carinii: oxygen uptake, antioxidant enzymes, and susceptibility to oxygen-mediated damage.

Authors:  E L Pesanti
Journal:  Infect Immun       Date:  1984-04       Impact factor: 3.441

3.  Exogenous heat-killed Escherichia coli improves alveolar macrophage activity and reduces Pneumocystis carinii lung burden in infant mice.

Authors:  Kerry M Empey; Melissa Hollifield; Beth A Garvy
Journal:  Infect Immun       Date:  2007-05-07       Impact factor: 3.441

4.  Phospholipid profile of Pneumocystis carinii and its interaction with alveolar type II epithelial cells.

Authors:  E L Pesanti
Journal:  Infect Immun       Date:  1987-03       Impact factor: 3.441

5.  Predisposing factors in Pneumocystis carinii pneumonia: effects of tetracycline, protein malnutrition, and corticosteroids on hosts.

Authors:  P D Walzer; M LaBine; T J Redington; M T Cushion
Journal:  Infect Immun       Date:  1984-12       Impact factor: 3.441

6.  Inhibitors of folic acid synthesis in the treatment of experimental Pneumocystis carinii pneumonia.

Authors:  P D Walzer; C K Kim; J M Foy; M J Linke; M T Cushion
Journal:  Antimicrob Agents Chemother       Date:  1988-01       Impact factor: 5.191

Review 7.  Incomplete immune recovery in HIV infection: mechanisms, relevance for clinical care, and possible solutions.

Authors:  Julie C Gaardbo; Hans J Hartling; Jan Gerstoft; Susanne D Nielsen
Journal:  Clin Dev Immunol       Date:  2012-03-14

8.  Thirty Years with HIV Infection-Nonprogression Is Still Puzzling: Lessons to Be Learned from Controllers and Long-Term Nonprogressors.

Authors:  Julie C Gaardbo; Hans J Hartling; Jan Gerstoft; Susanne D Nielsen
Journal:  AIDS Res Treat       Date:  2012-05-27

9.  Lethal exacerbation of Pneumocystis carinii pneumonia in severe combined immunodeficiency mice after infection by pneumonia virus of mice.

Authors:  J B Roths; A L Smith; C L Sidman
Journal:  J Exp Med       Date:  1993-04-01       Impact factor: 14.307

10.  Resolution of Pneumocystis carinii pneumonia in CD4+ lymphocyte-depleted mice given aerosols of heat-treated Escherichia coli.

Authors:  A G Harmsen; W Chen
Journal:  J Exp Med       Date:  1992-09-01       Impact factor: 14.307

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.